MY174727A - Stable, protracted glp-1/glucagon receptor co-agonists for medical use - Google Patents
Stable, protracted glp-1/glucagon receptor co-agonists for medical useInfo
- Publication number
- MY174727A MY174727A MYPI2015703258A MYPI2015703258A MY174727A MY 174727 A MY174727 A MY 174727A MY PI2015703258 A MYPI2015703258 A MY PI2015703258A MY PI2015703258 A MYPI2015703258 A MY PI2015703258A MY 174727 A MY174727 A MY 174727A
- Authority
- MY
- Malaysia
- Prior art keywords
- agonists
- stable
- glucagon receptor
- medical use
- protracted glp
- Prior art date
Links
- 108010063919 Glucagon Receptors Proteins 0.000 title abstract 2
- 102100040890 Glucagon receptor Human genes 0.000 title abstract 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13164272 | 2013-04-18 | ||
| US201361814969P | 2013-04-23 | 2013-04-23 | |
| EP13196656 | 2013-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY174727A true MY174727A (en) | 2020-05-11 |
Family
ID=51730843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015703258A MY174727A (en) | 2013-04-18 | 2014-04-22 | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9474790B2 (enExample) |
| EP (1) | EP2986313B1 (enExample) |
| JP (1) | JP6594856B2 (enExample) |
| KR (1) | KR20160021758A (enExample) |
| CN (1) | CN105307672B (enExample) |
| AU (1) | AU2014255608B2 (enExample) |
| BR (1) | BR112015025464A2 (enExample) |
| CA (1) | CA2909581A1 (enExample) |
| MX (1) | MX362275B (enExample) |
| MY (1) | MY174727A (enExample) |
| PL (1) | PL2986313T3 (enExample) |
| RS (1) | RS59124B1 (enExample) |
| RU (1) | RU2683039C2 (enExample) |
| SI (1) | SI2986313T1 (enExample) |
| WO (1) | WO2014170496A1 (enExample) |
| ZA (1) | ZA201507010B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX354705B (es) | 2011-09-23 | 2018-03-16 | Novo Nordisk As | Analogos de glucagon novedosos. |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| BR112015025464A2 (pt) | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
| HUE045573T2 (hu) * | 2013-04-18 | 2020-01-28 | Novo Nordisk As | Stabil, hosszú hatóidejû GLP-1/glükagon receptor ko-agonisták, gyógyászati alkalmazásra |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| CN117582516A (zh) * | 2014-05-28 | 2024-02-23 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| KR102291020B1 (ko) * | 2014-12-30 | 2021-08-20 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| FI3322437T3 (fi) | 2015-06-30 | 2024-02-20 | Hanmi Pharmaceutical Co Ltd | Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| RU2747877C2 (ru) * | 2016-01-13 | 2021-05-17 | Ново Нордиск А/С | Аналоги эфр(а) с заместителями - жирными кислотами |
| FR3050112B1 (fr) | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
| CN122440793A (zh) | 2016-06-29 | 2026-07-24 | 韩美药品株式会社 | 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途 |
| CN110945017B (zh) | 2017-07-19 | 2024-07-16 | 诺和诺德股份有限公司 | 双功能化合物 |
| GB201720187D0 (en) | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
| AU2019205905B2 (en) | 2018-01-03 | 2024-12-12 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for treatment of NASH and other disorders |
| PE20210473A1 (es) | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
| US20200268835A1 (en) | 2019-02-27 | 2020-08-27 | Novo Nordisk A/S | Compounds For Use in NASH |
| GB201908424D0 (en) | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
| CA3168001A1 (en) * | 2020-02-21 | 2021-08-26 | Spitfire Pharma Llc | Glp-1r and gcgr agonists, formulations, and methods of use |
| CN117202924A (zh) | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| TW202346323A (zh) | 2022-02-07 | 2023-12-01 | 英商梅迪繆思有限公司 | 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽 |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| IL93173A0 (en) | 1989-02-01 | 1990-11-05 | Shionogi & Co | Production of glucagon |
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5480867A (en) | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| CZ120398A3 (cs) | 1995-09-08 | 1998-12-16 | Novo Nordisk A/S | Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty |
| CZ220498A3 (cs) | 1996-01-17 | 1998-11-11 | Novo Nordisk A/S | Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití |
| WO1997041097A2 (en) | 1996-12-31 | 1997-11-06 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| JP2000514041A (ja) | 1996-07-26 | 2000-10-24 | ドクター・レディーズ・リサーチ・ファウンデーション | 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物 |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| EP0981526B1 (en) | 1997-05-02 | 2004-02-25 | Dr. Reddy's Laboratories Ltd. | Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| WO1999001423A1 (en) | 1997-07-01 | 1999-01-14 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| AU757693B2 (en) | 1997-07-16 | 2003-03-06 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| WO1998045292A1 (en) | 1997-12-02 | 1998-10-15 | Dr. Reddy's Research Foundation | Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties |
| EP1123297A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000023445A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000023416A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000023425A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| AU6190199A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
| EP1123269A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| KR20010086126A (ko) | 1998-12-18 | 2001-09-07 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 융합된 1,2,4-티아디아진 유도체 및 그의 제법 및 용도 |
| WO2000041121A1 (en) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Method and arrangement for issuance and management of digital coupons and sales offers |
| AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| WO2000042023A1 (en) | 1999-01-18 | 2000-07-20 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| WO2000063189A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate |
| AU2953699A (en) | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
| EP1173438A1 (en) | 1999-04-16 | 2002-01-23 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| IL145958A0 (en) | 1999-04-16 | 2002-07-25 | Reddy Research Foundation | Polymorphic form of arginine salt of (2s)-3-[4-[2-phenoxazin-10-yl)ethoxy] phenyl]2-ethoxypropanoic acid, processes for the preparation thereof and pharmaceutical compositions containing the same |
| JP2002542246A (ja) | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造及び使用 |
| EP1171431A1 (en) | 1999-04-20 | 2002-01-16 | Novo Nordisk A/S | Compounds, their preparation and use |
| HUP0200807A3 (en) | 1999-04-20 | 2003-03-28 | Novo Nordisk As | Substituted propionic acid derivatives, process for their preparation, pharmaceutical compositions containing them and their use |
| AU3958200A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000064884A1 (en) | 1999-04-26 | 2000-11-02 | Novo Nordisk A/S | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
| PT1180121E (pt) | 1999-05-17 | 2004-03-31 | Conjuchem Inc | Peptidos insulinotropicos de longa duracao |
| AU765753B2 (en) | 1999-05-17 | 2003-09-25 | Conjuchem Biotechnologies Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| DE60137876D1 (de) | 2000-06-16 | 2009-04-16 | Lilly Co Eli | Analoge des Glucagon-ähnlichen Peptids-1 |
| CA2416229C (en) | 2000-07-20 | 2007-09-18 | F. Hoffmann-La Roche Ag | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| EP2292273A3 (en) | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US8048408B2 (en) | 2002-01-16 | 2011-11-01 | Biocompatibles Uk Limited | Polymer conjugates |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| NZ541365A (en) | 2002-12-27 | 2009-09-25 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| EP1503283A1 (en) | 2003-08-01 | 2005-02-02 | Hewlett-Packard Development Company, L.P. | Data processing system and method |
| AU2004261353B2 (en) | 2003-08-05 | 2009-12-10 | Novo Nordisk A/S | Novel insulin derivatives |
| EP1654290B1 (en) | 2003-08-12 | 2019-03-13 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| RU2401276C2 (ru) | 2003-09-19 | 2010-10-10 | Ново Нордиск А/С | Производные глюкагон-подобного пептида-1 (glp-1) |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| DK2371856T3 (en) | 2004-11-12 | 2022-08-08 | Bayer Healthcare Llc | Site-directed modifikation af FVIII |
| US8217154B2 (en) | 2005-02-23 | 2012-07-10 | Lipoxen Technologies Limited | Activated sialic acid derivatives for protein derivatisation and conjugation |
| EP1863537A2 (en) | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US20080227691A1 (en) | 2005-04-01 | 2008-09-18 | Novo Nordisk Health Care Ag | Blood Coagulation FVIII Analogues |
| EP1891105B1 (en) | 2005-06-13 | 2012-04-11 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
| BRPI0611570A2 (pt) | 2005-06-15 | 2011-02-22 | Novo Nordisk Healthcare Ag | métodos para fixar covalentemente peg a um polipeptìdeo e para modificar propriedades farmacológicas de hormÈnio de crescimento, composto e sais, pró-drogas ou solvatos farmaceuticamente aceitáveis do mesmo, hormÈnio de crescimento humano, composição farmacêutica, método para tratamento de doença e, uso de um composto |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| CA2913805A1 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| WO2007087711A1 (en) | 2006-01-31 | 2007-08-09 | National Research Council Of Canada | Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase |
| EP2471810A1 (en) | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| WO2007126808A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc | Pegylated factor viii |
| CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| DK2101821T3 (da) | 2006-12-15 | 2014-10-06 | Baxter Healthcare Sa | Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo |
| CN101578102B (zh) | 2007-01-05 | 2013-07-17 | 印第安纳大学研究及科技有限公司 | 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物 |
| NZ578948A (en) | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| EP2162535A4 (en) | 2007-06-04 | 2011-02-23 | Novo Nordisk As | O-linked glycosylation using N-acetylglucosamine transferases |
| WO2008152403A1 (en) | 2007-06-15 | 2008-12-18 | Zealand Pharma A/S | Glucagon analogues |
| US8460909B2 (en) | 2007-06-15 | 2013-06-11 | National Research Council Of Canada | Engineered versions of polysialyltransferases with enhanced enzymatic properties |
| EP2190872B1 (en) * | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| JP2010538996A (ja) * | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 単独またはＴｈｒ−Ｔｈｒ−Ｓｅｒ−Ｇｌｎ−Ｖａｌ−Ａｒｇ−Ｐｒｏ−Ａｒｇ−ＯＨのペプチドとの組合せにおけるＡｓｎ−Ａｓｐ−Ａｓｐ−Ｃｙｓ−Ｇｌｕ−Ｌｅｕ−Ｃｙｓ−Ｖａｌ−Ａｓｎ−Ｖａｌ−Ａｌａ−Ｃｙｓ−Ｔｈｒ−Ｇｌｙ−Ｃｙｓ−Ｌｅｕ−ＯＨのペプチドの治療剤としての使用 |
| AU2008323768A1 (en) | 2007-11-09 | 2009-05-14 | Baxter Healthcare S.A. | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| CN102037004A (zh) | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
| US20110065633A1 (en) | 2008-01-30 | 2011-03-17 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
| ES2558842T3 (es) | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| TWI541023B (zh) | 2008-06-17 | 2016-07-11 | 印第安納大學科技研究公司 | 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物 |
| CA2728284C (en) | 2008-06-17 | 2019-09-10 | Richard D. Dimarchi | Glucagon/glp-1 receptor co-agonists |
| CA2732949C (en) * | 2008-08-07 | 2016-12-20 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
| PT2349342T (pt) | 2008-10-17 | 2018-10-26 | Baxalta Inc | Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água |
| US8642540B2 (en) | 2008-12-15 | 2014-02-04 | Zealand Pharma A/S | Glucagon analogues |
| ES2502218T3 (es) * | 2008-12-15 | 2014-10-03 | Zealand Pharma A/S | Análogos de glucagón |
| MA32970B1 (fr) | 2008-12-15 | 2012-01-02 | Zealand Pharma As | Analogues du glucagon |
| AU2008365557A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| US20110306551A1 (en) | 2009-02-19 | 2011-12-15 | Novo Nordisk A/S | Modification of Factor VIII |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2011088837A1 (en) | 2010-01-20 | 2011-07-28 | Zealand Pharma A/S | Treatment of cardiac conditions |
| KR20130018410A (ko) | 2010-03-26 | 2013-02-21 | 노보 노르디스크 에이/에스 | 새로운 글루카곤 유사체 |
| AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| WO2011117417A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| CA2802897A1 (en) | 2010-06-24 | 2011-12-29 | Zealand Pharma A/S | Glucagon analogues |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
| RU2013133803A (ru) * | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| NZ612297A (en) * | 2010-12-22 | 2015-10-30 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
| EA201390796A1 (ru) | 2011-01-20 | 2014-07-30 | Зилэнд Фарма А/С | Применение ацилированного аналога глюкагона |
| RU2013145013A (ru) | 2011-03-28 | 2015-05-10 | Ново Нордиск А/С | Новые аналоги глюкагона |
| US9790262B2 (en) | 2011-04-05 | 2017-10-17 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| EP4286400A3 (en) | 2011-05-18 | 2024-06-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| CA3134906A1 (en) | 2011-05-18 | 2012-11-22 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| HRP20181591T1 (hr) | 2011-06-10 | 2018-11-30 | Hanmi Science Co., Ltd. | Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže |
| JP6184404B2 (ja) * | 2011-06-22 | 2017-08-23 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | グルカゴン／ｇｌｐ−１レセプターコアゴニスト |
| CN103857408B (zh) | 2011-06-22 | 2017-04-12 | 印第安那大学科技研究公司 | 胰高血糖素/glp‑1受体协同激动剂 |
| MX354705B (es) | 2011-09-23 | 2018-03-16 | Novo Nordisk As | Analogos de glucagon novedosos. |
| BR112015025464A2 (pt) | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
| TW201609797A (zh) * | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
-
2014
- 2014-04-22 BR BR112015025464A patent/BR112015025464A2/pt not_active IP Right Cessation
- 2014-04-22 AU AU2014255608A patent/AU2014255608B2/en not_active Ceased
- 2014-04-22 CN CN201480034914.8A patent/CN105307672B/zh active Active
- 2014-04-22 JP JP2016508190A patent/JP6594856B2/ja active Active
- 2014-04-22 PL PL14719715T patent/PL2986313T3/pl unknown
- 2014-04-22 EP EP14719715.6A patent/EP2986313B1/en active Active
- 2014-04-22 RS RS20191031A patent/RS59124B1/sr unknown
- 2014-04-22 WO PCT/EP2014/058084 patent/WO2014170496A1/en not_active Ceased
- 2014-04-22 CA CA2909581A patent/CA2909581A1/en not_active Withdrawn
- 2014-04-22 RU RU2015146600A patent/RU2683039C2/ru active
- 2014-04-22 MX MX2015014408A patent/MX362275B/es active IP Right Grant
- 2014-04-22 MY MYPI2015703258A patent/MY174727A/en unknown
- 2014-04-22 SI SI201431291T patent/SI2986313T1/sl unknown
- 2014-04-22 KR KR1020157032329A patent/KR20160021758A/ko not_active Withdrawn
-
2015
- 2015-08-26 US US14/836,192 patent/US9474790B2/en active Active
- 2015-09-21 ZA ZA2015/07010A patent/ZA201507010B/en unknown
-
2016
- 2016-06-10 US US15/179,316 patent/US9751927B2/en active Active
-
2017
- 2017-08-15 US US15/677,585 patent/US20180044394A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016526012A (ja) | 2016-09-01 |
| AU2014255608A1 (en) | 2015-10-08 |
| PL2986313T3 (pl) | 2019-12-31 |
| MX362275B (es) | 2019-01-10 |
| RU2015146600A (ru) | 2017-05-24 |
| CN105307672B (zh) | 2021-01-05 |
| RU2015146600A3 (enExample) | 2018-03-29 |
| SI2986313T1 (sl) | 2019-09-30 |
| MX2015014408A (es) | 2017-07-28 |
| US9474790B2 (en) | 2016-10-25 |
| US20160355562A1 (en) | 2016-12-08 |
| CA2909581A1 (en) | 2014-10-23 |
| WO2014170496A1 (en) | 2014-10-23 |
| EP2986313A1 (en) | 2016-02-24 |
| JP6594856B2 (ja) | 2019-10-23 |
| ZA201507010B (en) | 2017-08-30 |
| KR20160021758A (ko) | 2016-02-26 |
| EP2986313B1 (en) | 2019-06-12 |
| US9751927B2 (en) | 2017-09-05 |
| BR112015025464A2 (pt) | 2017-10-10 |
| US20150374794A1 (en) | 2015-12-31 |
| AU2014255608B2 (en) | 2018-01-25 |
| RU2683039C2 (ru) | 2019-03-26 |
| US20180044394A1 (en) | 2018-02-15 |
| CN105307672A (zh) | 2016-02-03 |
| RS59124B1 (sr) | 2019-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015014408A (es) | Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico. | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| PH12014502058A1 (en) | Pharmaceutical composition comprising empagliflozin and antiobesity drug | |
| PH12015500115B1 (en) | Glucagon analogues | |
| MY167234A (en) | Novel glucagon analogues | |
| MX380273B (es) | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp. | |
| PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| IL239488A0 (en) | A gpc3-targeted medicinal agent for the treatment of patients for whom treatment with a gpc3-targeted medicinal agent is beneficial | |
| EP3141603A4 (en) | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective | |
| MX373851B (es) | Métodos de administración de tratamiento con pirfenidona. | |
| MX2015015249A (es) | Peptidos terapeuticos. | |
| MX370953B (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| PH12016500978A1 (en) | Piperazine derivatives having multimodal activity against pain | |
| EP3318879A4 (en) | Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag | |
| MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| IL245738A0 (en) | Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases | |
| MX2016006688A (es) | Inhibidores tetraciclicos de autotaxina. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2015013091A (es) | Metodos mejorados de uso para secretoglobinas humanas recombinantes. | |
| MX2016006603A (es) | Compuestos piperidinicos con actividad multimodal contra el dolor. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| GB201304462D0 (en) | Therapeutic vaccine for treatment of type 2 diabetes and impaired glucose tolerance | |
| UA78287U (ru) | Способ медицинской реабилитации больных ишемической болезнью сердца на фоне метаболического синдрома | |
| PL2852400T3 (pl) | Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy |